Last update 24 May 2025

CD200AR-L

Overview

Basic Info

Drug Type
Recombinant polypeptide
Synonyms
CD200AR L, hP1A8
Target
CD200
Action
inhibitors
Mechanism
CD200 inhibitors(OX-2 membrane glycoprotein inhibitors)
Therapeutic Areas
NeoplasmsNervous System DiseasesOther Diseases
Active Indication-
Inactive Indication
Recurrent Glioblastoma
Originator Organization
OX2 Therapeutics, Inc.OX2 Therapeutics, Inc.
Active Organization-
Inactive Organization
OX2 Therapeutics, Inc.OX2 Therapeutics, Inc.
License Organization-
Drug Highest PhasePendingPhase 1
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Related

1
Clinical Trials associated with CD200AR-L
NCT04642937
/ Unknown statusPhase 1
Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent Glioblastoma
100 Clinical Results associated with CD200AR-L
Login to view more data
100 Translational Medicine associated with CD200AR-L
Login to view more data
100 Patents (Medical) associated with CD200AR-L
Login to view more data
100 Deals associated with CD200AR-L
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Recurrent GlioblastomaPhase 1
United States
OX2 Therapeutics, Inc.OX2 Therapeutics, Inc.
01 Dec 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free